Firm is cited in a June 20 FDA 1warning letter for failing to perform some sponsor obligations in pivotal and pilot investigational device studies. The letter comes on the heels of Synapse's June 17 FDA approval for its NeuRx DPS diaphragm pacing system for certain spinal cord injury patients via humanitarian device exemption (HDE). NeuRx DPS stimulates the diaphragm and allows patients to breathe for at least four hours a day without a mechanical ventilator. According to the letter, based on an inspection conducted Feb. 25-March 18, Synapse expanded one study to four additional clinical sites without prior FDA approval. The firm also failed to adequately monitor the studies and obtain signed agreements from each investigator with full financial disclosure information. Synapse also shipped replacement parts for the device directly to trial subjects. CEO Anthony Ignagni says the issues are not related to product quality or performance and do not preclude the firm from shipping its products for use in spinal cord injury patients or in clinical trials of patients with amyotrophic lateral sclerosis (2"The Gray Sheet" June 23, 2008, p. 21)
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
After receiving FDA clearance for its Genio sleep apnea implant, Nyxoah plans a major US rollout despite a patent suit from rival Inspire Medical. Genio offers bilateral nerve stimulation as a CPAP alternative, with strong trial results.
Draeger Medical has recalled certain SafeStar and TwinStar ventilation filters after reports of serious injuries caused by misleading carbon dioxide readings.
The UK device regulator wants to align health institution device exemptions with its evolving policy of agile regulation of medtech in the British market. It asks stakeholders to complete a survey by Sept. 15.
